Related Experiment Video
Updated: May 29, 2026

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking (TXL) for Myopia
Published on: January 6, 2018
Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis
Paul S Tlucek1, Donald U Stone
1Department of Ophthalmology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA.
Purpose:
To report the successful treatment of rheumatoid arthritis (RA)-associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol.
Methods:
Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process.
Results:
Six months after beginning the new therapy, it was well-tolerated and the patient's RA and scleritis were quiescent.
Conclusions:
Certolizumab pegol may successfully treat RA-associated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Constipation-Predominant IBS
